Latest Close
$3.98
News
CRVO
CervoMed Inc. News
This news view pulls recent coverage and headlines tied to CRVO.
1y Change
-$5.32 (-57.20%)
Market Cap
$36,849,700.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
GlobeNewswire • Apr 7, 2026
Read articleCervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
Insider Monkey • Mar 25, 2026
Read articleCervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
GlobeNewswire • Mar 19, 2026
Read articleChardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating
MT Newswires • Mar 18, 2026
Read articleCervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
GlobeNewswire • Mar 17, 2026
Read articleCervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
Zacks • Mar 13, 2026
Read article